OncoSec Medical Inc. (OTCQB: ONCS),
a company developing DNA-based intratumoral cancer immunotherapies, will
present at three events in November. The Company’s agenda is as follows:
BIO-Europe International Partnering Conference
Dr. Robert H. Pierce, Chief Scientific Officer, will present a corporate
overview of the Company at the 20th Annual BIO Europe International
Partnering Conference, taking place November 3-5, 2014 in Frankfurt,
Germany. The presentation is part of the Immunotherapy track and is
scheduled to begin at 11:30 AM CET on Tuesday, November 4th.
BIO-Europe® is Europe's largest partnering conference serving
the global biotechnology industry. The conference annually attracts
leading dealmakers from biotech, pharma and finance along with the most
exciting emerging companies. Produced with the support of BIO, it is
regarded as a “must attend” event for the biotech industry. For more
information, please visit http://www.ebdgroup.com/bioeurope/index.php
Drexel Hamilton Micro-Cap Investor Forum
Jordyn Kopin, Associate Director of Corporate Communications, will
present a corporate overview of the Company at the Drexel Hamilton
Micro-Cap Investor Forum, taking place November 13th, 2014 in New York
City, New York. The presentation is scheduled to begin at 10 AM EST.
The Drexel Hamilton Micro-Cap Investor Forum is an interactive industry
conference for institutional investors. The conference will feature
one-on-one meeting opportunities with presenting companies and provide
an interactive environment meant to facilitate networking and
discussion. For more information, please visit http://drexelhamilton.com/research/conferences/
Brean Capital Life Sciences Summit Conference
Punit Dhillon, President and CEO, will present a corporate overview of
the company at the Brean Capital Life Sciences Summit. The event will
take place November 24th, 2014 in New York City, New York.
The Brean Capital Life Sciences Summit is an industry-specific
investment conference designed to facilitate the interaction of company
management and institutional investors. The goal of each Brean Capital
conference is to provide institutional investors with high-level access
to senior management and industry experts and designed to connect the
dots and provide original outlook and depth. For more information please
visit: http://www.breancapital.com/profile/conferences/
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core
technology is designed to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of various
skin cancers, as well as the potential to initiate a systemic immune
response without the systemic toxicities associated with other
treatments. OncoSec's lead program evaluating ImmunoPulse for the
treatment of metastatic melanoma is currently in Phase 2 development,
and is being conducted in collaboration with several prominent academic
medical centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and developing
new immune-targeting agents, investigating additional tumor indications,
and evaluating combination-based immunotherapy approaches. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014